Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

BET Bromodomain Proteins Mediate Downstream Signaling Events following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosis

Xiaoyan Tang, Ruoqi Peng, Yonglin Ren, Subramanium Apparsundaram, Jeremy Deguzman, Carla M. Bauer, Ann F. Hoffman, Shannon Hamilton, Zhenmin Liang, Hang Zeng, Maria E. Fuentes, Julie A. DeMartino, Christopher Kitson, Christopher S. Stevenson and David C. Budd
Molecular Pharmacology January 2013, 83 (1) 283-293; DOI: https://doi.org/10.1124/mol.112.081661
Xiaoyan Tang
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruoqi Peng
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yonglin Ren
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subramanium Apparsundaram
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Deguzman
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla M. Bauer
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann F. Hoffman
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shannon Hamilton
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenmin Liang
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hang Zeng
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria E. Fuentes
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie A. DeMartino
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Kitson
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher S. Stevenson
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Budd
Inflammation Discovery Therapeutic Area (X.T., R.P., Y.R., S.A., J.D., C.M.B., M.E.F., J.A.D., C.K., C.S.S., D.C.B.); Early ADME (DMPK) (Z.L., H.Z.); RDT–Discovery Technologies (A.F.H., S.H.); Hoffmann-La Roche Inc., Nutley, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Epigenetic alterations, such as histone acetylation, regulate the signaling outcomes and phenotypic responses of fibroblasts after growth factor stimulation. The bromodomain and extra-terminal domain–containing proteins (Brd) bind to acetylated histone residues, resulting in recruitment of components of the transcriptional machinery and subsequent gene transcription. Given the central importance of fibroblasts in tissue fibrosis, this study sought to determine the role of Brd proteins in human lung fibroblasts (LFs) after growth factor stimulation and in the murine bleomycin model of lung fibrosis. Using small interfering RNA against human Brd2 and Brd4 and pharmacologic Brd inhibitors, this study found that Brd2 and Brd4 are essential in mediating the phenotypic responses of LFs downstream of multiple growth factor pathways. Growth factor stimulation of LFs causes increased histone acetylation, association of Brd4 with growth factor–responsive genes, and enhanced transcription of these genes that could be attenuated with pharmacologic Brd inhibitors. Of note, lung fibrosis induced after intratracheal bleomycin challenge in mice could be prevented by pretreatment of animals with pharmacologic inhibitors of Brd proteins. This study is the first demonstration of a role for Brd2 and Brd4 proteins in mediating the responses of LFs after growth factor stimulation and in driving the induction of lung fibrosis in mice in response to bleomycin challenge.

Footnotes

  • ↵Embedded ImageThis article has supplemental material available at mol.aspetjournals.org.

  • This work was supported by Hoffmann-La Roche Inc.

  • dx.doi.org/10.1124/mol.112.081661.

  • Received August 16, 2012.
  • Accepted October 23, 2012.
  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 83 (1)
Molecular Pharmacology
Vol. 83, Issue 1
1 Jan 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BET Bromodomain Proteins Mediate Downstream Signaling Events following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosis
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Brd Proteins Mediate Lung Fibrosis

Xiaoyan Tang, Ruoqi Peng, Yonglin Ren, Subramanium Apparsundaram, Jeremy Deguzman, Carla M. Bauer, Ann F. Hoffman, Shannon Hamilton, Zhenmin Liang, Hang Zeng, Maria E. Fuentes, Julie A. DeMartino, Christopher Kitson, Christopher S. Stevenson and David C. Budd
Molecular Pharmacology January 1, 2013, 83 (1) 283-293; DOI: https://doi.org/10.1124/mol.112.081661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Brd Proteins Mediate Lung Fibrosis

Xiaoyan Tang, Ruoqi Peng, Yonglin Ren, Subramanium Apparsundaram, Jeremy Deguzman, Carla M. Bauer, Ann F. Hoffman, Shannon Hamilton, Zhenmin Liang, Hang Zeng, Maria E. Fuentes, Julie A. DeMartino, Christopher Kitson, Christopher S. Stevenson and David C. Budd
Molecular Pharmacology January 1, 2013, 83 (1) 283-293; DOI: https://doi.org/10.1124/mol.112.081661
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contribution
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics